List of Excipients in Branded Drug SOLU-MEDROL

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Pharmacia & Upjohn Company LLC	SOLU-MEDROL	methylprednisolone sodium succinate	0009-0698	BENZYL ALCOHOL
Pharmacia & Upjohn Company LLC	SOLU-MEDROL	methylprednisolone sodium succinate	0009-0698	SODIUM PHOSPHATE, DIBASIC
Pharmacia & Upjohn Company LLC	SOLU-MEDROL	methylprednisolone sodium succinate	0009-0698	SODIUM PHOSPHATE, MONOBASIC, ANHYDROUS
Pharmacia & Upjohn Company LLC	SOLU-MEDROL	methylprednisolone sodium succinate	0009-0758	SODIUM PHOSPHATE, DIBASIC

# SOLU-MEDROL Excipient Strategy, Patent Position, and Commercial Opportunities

Last updated: September 16, 2026

Solu-Medrol is the branded injectable form of methylprednisolone sodium succinate, a water-soluble corticosteroid used when parenteral corticosteroid therapy is required. Its commercial value is tied less to patent exclusivity than to hospital procurement, emergency-use reliability, dosage-form convenience, supply continuity, and excipient differentiation. The strongest opportunities are ready-to-use presentations, low-volume high-concentration products, dual-chamber systems, premixed infusion bags, and formulations that address lactose sensitivity, particulate control, and extended in-use handling.

What is Solu-Medrol and which excipients does it contain?

Solu-Medrol contains methylprednisolone sodium succinate, a prodrug salt designed for rapid dissolution and intravenous or intramuscular administration. Pfizer markets the product in single-dose and Act-O-Vial presentations containing a sterile powder and a separate diluent chamber. The FDA-approved label identifies inactive ingredients that include phosphate buffers and, in specified presentations, lactose monohydrate.[1]

Product attribute	Solu-Medrol profile
Active ingredient	Methylprednisolone sodium succinate
Pharmacologic class	Glucocorticoid corticosteroid
Routes	Intravenous and intramuscular
Primary dosage forms	Sterile powder, dual-chamber Act-O-Vial
Common strengths	40 mg, 125 mg, 500 mg, 1,000 mg, with presentation-specific configurations
Preservative profile	Product-specific; single-dose configurations are generally used for parenteral administration
Key excipient functions	Buffering, reconstitution performance, pH control, cake stability, and dosage-form usability
Original sponsor	The Upjohn Company, now within Pfizer’s commercial portfolio
Regulatory status	FDA-approved legacy injectable corticosteroid

The excipient package must maintain methylprednisolone sodium succinate in a stable, rapidly reconstitutable sterile cake. The formulation also must control pH, minimize degradation during storage, and support visual inspection for particulates and discoloration.

The 40 mg presentation has received particular attention because of lactose content and the potential relevance of cow’s-milk protein hypersensitivity in susceptible patients. The product label includes a warning concerning the presence of lactose derived from cow’s milk in the 40 mg formulation.[1] This creates a commercial opening for a lactose-free alternative, provided the replacement excipient system preserves stability, sterility, reconstitution time, and container closure performance.

What excipient strategy best supports a Solu-Medrol competitor?

A successful competitor should treat excipients as a product-design platform rather than as low-cost inactive ingredients. The formulation strategy should address five commercial requirements: rapid reconstitution, storage stability, compatibility with common infusion fluids, low particulate burden, and operational simplicity for hospital staff.

Buffer and pH-control strategy

Methylprednisolone sodium succinate is highly water-soluble, but the formulation remains sensitive to pH, ionic environment, and storage conditions. Phosphate buffering can support pH control and reconstitution performance. A development program should evaluate:

• Monobasic and dibasic phosphate ratios.
• Citrate or other buffer systems as alternatives where compatibility permits.
• Buffer concentration and its effect on osmolality.
• pH drift after reconstitution.
• Compatibility with 0.9% sodium chloride and 5% dextrose.
• Precipitation risk after dilution into infusion containers.

The commercial objective is not simply to match the reference formulation. A differentiated buffer system could support longer in-use stability or broader compatibility with hospital admixture practices.

Lactose-free formulation

A lactose-free 40 mg presentation is one of the clearest excipient opportunities. The alternative should replace lactose with an excipient that supports cake structure and reconstitution without introducing a new allergen, excessive osmolality, or unacceptable residual moisture.

Potential development candidates include mannitol, sucrose, trehalose, or glycine, subject to compatibility and injectable-use requirements. Each candidate creates different technical tradeoffs:

Excipient candidate	Potential benefit	Main development issue
Mannitol	Common bulking agent, low reducing activity, useful cake structure	May alter tonicity and cake morphology
Sucrose	Strong glass-forming and stabilizing properties	Requires control of residual moisture and hydrolysis
Trehalose	High glass-transition temperature and stabilization potential	Cost and injectable formulation precedent
Glycine	Buffering and bulking utility	May affect pH and solubility behavior
Lactose replacement blend	Can optimize cake and reconstitution performance	More complex regulatory and manufacturing package

A lactose-free label claim would have commercial value in hospitals treating patients with milk-protein allergy concerns. The claim must be supported by raw-material controls, supplier qualification, and testing for residual milk proteins where relevant.

Preservative-free and low-excipient design

Hospitals generally favor single-dose, preservative-free injectable products when the clinical setting allows. A preservative-free composition can reduce concerns related to benzyl alcohol and other antimicrobial agents, especially in neonatal, pediatric, and high-acuity settings.

The commercial challenge is microbial control. The product must rely on validated aseptic processing, container closure integrity, and single-use labeling. A preservative-free formulation paired with a ready-to-use or dual-chamber delivery system can create a stronger value proposition than a simple powder-for-injection generic.

Reconstitution and handling performance

Reconstitution time is a practical purchasing factor. Emergency departments, intensive-care units, operating rooms, and ambulances benefit from products that minimize steps and reduce the risk of preparation errors.

Performance targets should include:

• Short reconstitution time with standard diluents.
• No foaming or excessive agitation requirement.
• Clear solution after reconstitution.
• Low extractables and leachables from the vial or device.
• Defined in-use stability after activation.
• Easy differentiation between powder and diluent chambers.
• Reduced risk of incorrect diluent selection.

Solu-Medrol’s Act-O-Vial architecture already addresses some workflow barriers. A competing product needs either a lower total preparation burden or a meaningful cost and supply advantage.

What formulations are protected by Solu-Medrol patents?

Solu-Medrol is a legacy product. The principal commercial protection historically came from the active ingredient and early formulation development, not from a current, durable patent moat. Methylprednisolone sodium succinate has been marketed for decades, and generic versions have entered the U.S. market.

Protection category	Commercial assessment
Active ingredient patent	Expired legacy protection
Core injectable formulation	No meaningful current exclusivity identified
Act-O-Vial device concept	Potentially relevant historical or device-related rights, but not a broad barrier to generic powder products
Method-of-use patents	No material blocking estate identified for standard corticosteroid indications
Manufacturing patents	Process know-how may remain valuable, but does not generally block an abbreviated new drug application
Orange Book position	The product is subject to generic competition; no commercially significant unexpired patent barrier is generally associated with the legacy product

Patent rights should be separated from regulatory exclusivity. FDA approval of a generic methylprednisolone sodium succinate product does not require freedom to copy every commercial presentation, label design, or delivery device. A manufacturer can pursue a conventional sterile powder vial without copying the Act-O-Vial configuration.

When does Solu-Medrol lose exclusivity?

Solu-Medrol has already lost the market exclusivity associated with its original active ingredient and core injectable technology. The product is commercially exposed to generic competition, and purchasing decisions are driven by price, supply reliability, contract access, and dosage-form convenience.

The principal regulatory pathways are:

• Abbreviated New Drug Application for methylprednisolone sodium succinate injection.
• Section 505(b)(2) application for a materially differentiated presentation, delivery system, or formulation.
• New drug application for a novel ready-to-use product or device combination where the reference product does not provide a sufficient bridge.

A standard generic powder vial generally has the clearest path under an ANDA. A ready-to-use liquid, extended-stability product, or advanced dual-chamber system may require a 505(b)(2) strategy depending on formulation, device, and reliance on the reference product.

What is the Orange Book status of Solu-Medrol?

The Orange Book identifies approved drug products and relevant patent and exclusivity information. For a legacy methylprednisolone sodium succinate product, the practical Orange Book issue is not an active patent barrier but the scope of the reference-listed drug and the presentation a generic applicant selects.[2]

A competitor should distinguish among:

1. The active ingredient and route.
2. Strength and dosage form.
3. Single-dose vial versus dual-chamber system.
4. Powder-for-injection versus ready-to-use solution.
5. Labeling carve-outs for protected indications, if any.
6. Device-specific rights outside the core drug approval.

A Paragraph IV certification is generally relevant only if the ANDA applicant identifies an unexpired listed patent. For the legacy Solu-Medrol franchise, standard generic entry is more likely to proceed through ordinary bioequivalence and patent certifications than through a high-value patent challenge.

Which companies compete with Solu-Medrol?

The competitive field includes generic injectable manufacturers, hospital-focused suppliers, and specialty manufacturers with sterile fill-finish capacity. Competition is strongest in standard vial presentations and weaker in differentiated delivery systems.

Relevant competitor groups include:

Competitor group	Competitive strength
Large generic injectables manufacturers	Scale, hospital contracts, broad portfolios
Specialty sterile manufacturers	Flexible presentation development and shortage response
Contract manufacturers	Low-cost production and private-label supply
Branded hospital suppliers	Distribution reach and procurement relationships
Device-integrated product developers	Ready-to-use and dual-chamber differentiation

Generic methylprednisolone sodium succinate products are listed in FDA drug databases and may be supplied by multiple manufacturers over time.[3] Product availability can change because sterile injectable markets are vulnerable to manufacturing interruptions, facility remediation, raw-material shortages, and limited supplier redundancy.

What commercial opportunities exist for a new Solu-Medrol formulation?

The largest opportunities are operational rather than pharmacologic.

Ready-to-use liquid injection

A ready-to-use product can eliminate powder reconstitution and reduce medication-preparation time. The main technical barriers are chemical stability, container compatibility, oxidation control, pH management, and shelf-life. A ready-to-use product also requires a strong particulate and extractables profile.

Potential formats include:

• Small-volume glass vials.
• Polymer vials or cartridges.
• Prefilled syringes for controlled settings.
• Premixed infusion bags for selected doses.
• Pharmacy bulk packages where permitted.

The strongest initial market is likely acute-care hospitals and emergency settings, where preparation time and error reduction have direct operational value.

Dual-chamber device with improved workflow

A next-generation dual-chamber system could compete directly with Act-O-Vial while offering:

• More intuitive activation.
• Better visual confirmation of mixing.
• Lower activation force.
• Improved labeling and barcode placement.
• Longer post-activation stability.
• Compatibility with automated medication cabinets.

Device patents may provide more defensible protection than the underlying drug. The applicant should seek claims covering chamber geometry, stopper design, activation mechanics, mixing pathway, and container closure integrity.

Lactose-free 40 mg presentation

This is a focused niche opportunity with a clear label-based differentiation. Hospitals may prefer a lactose-free version for patients with documented cow’s-milk protein hypersensitivity or where pharmacy protocols avoid lactose-containing parenteral products.

The product should avoid an overbroad claim that conflates lactose intolerance with milk-protein allergy. The relevant commercial issue is the excipient source and potential residual protein risk, not ordinary dietary lactose intolerance.

Extended in-use stability

A product that remains stable for a defined period after reconstitution or dilution could reduce waste. This benefit has practical value in emergency departments and infusion centers, where unused doses may otherwise be discarded.

Claims may be supported by:

• Specific buffer concentrations.
• Antioxidant control.
• Container closure selection.
• Light protection.
• Defined dilution matrices.
• Temperature-controlled storage instructions.

Supply-resilient manufacturing

Sterile injectable procurement increasingly rewards dependable supply. A manufacturer with multiple qualified fill-finish sites, dual-source excipients, and validated alternate container systems can compete even without the lowest unit price.

Manufacturing differentiation may include:

• Domestic and international fill-finish redundancy.
• Multiple approved raw-material suppliers.
• Reduced dependence on specialized dual-chamber components.
• Higher batch yields.
• Automated visual inspection.
• Shorter release testing cycles.

What patent and IP strategy can protect a Solu-Medrol competitor?

A new entrant should avoid relying on composition-of-matter protection. The stronger strategy is layered protection across formulation, device, manufacturing, and use.

IP layer	Potential claim subject
Formulation	Lactose-free composition, buffer system, stabilizer combination
Reconstitution	Defined dissolution time, clarity, pH, and post-mixing stability
Ready-to-use product	Liquid stability, antioxidant system, container compatibility
Device	Dual-chamber geometry, activation mechanism, mixing pathway
Packaging	Light protection, oxygen control, tamper evidence
Manufacturing	Lyophilization cycle, residual moisture control, aseptic process
Labeling	Supported handling or storage instructions
Trade secrets	Cycle parameters, supplier specifications, fill-finish controls

A formulation patent should include composition ranges, stability data, and alternative excipient embodiments. A device patent should be filed early because public disclosure of the delivery system can limit foreign rights and weaken novelty.

What generic launch scenarios exist for Solu-Medrol?

Standard generic vial

This is the fastest and most price-sensitive route. The product competes primarily on acquisition cost, supply history, wholesaler access, and hospital formulary placement.

Premium generic with lactose-free positioning

This product may command a moderate premium if supported by clear labeling, reliable supply, and pharmacy acceptance. The market is narrower but less commoditized.

Ready-to-use product

This option has a higher development burden and potentially stronger commercial differentiation. Pricing can reflect reduced preparation time, lower waste, and fewer pharmacy compounding steps.

Device-based 505(b)(2) product

A redesigned dual-chamber or administration system can create a proprietary product profile. The regulatory path, device development, human factors work, and manufacturing validation are more demanding than for a conventional ANDA.

What is the revenue exposure for Pfizer?

Pfizer does not generally report Solu-Medrol revenue as a standalone line item in public financial disclosures. The product is part of a broader established-products portfolio, and its revenue contribution is likely influenced by generic erosion, hospital contracting, product availability, and geographic sales mix.[4]

The commercial exposure is therefore best assessed through product-level sales data, tender awards, unit volumes, and channel pricing rather than Pfizer’s consolidated reporting. A competitor should not assume that a legacy branded injectable has lost all value. Hospitals may retain the brand where supply reliability, familiarity, and contracting outweigh the generic price difference.

What patent litigation and Paragraph IV risk affect Solu-Medrol?

No major current patent litigation barrier is generally associated with the core methylprednisolone sodium succinate injectable market. The principal legal risks for a new entrant are more likely to involve:

• Device patent claims covering a dual-chamber system.
• Trade dress or packaging disputes.
• Manufacturing know-how.
• Misbranding or unsupported comparative claims.
• Sterile manufacturing compliance.
• Product liability linked to reconstitution or particulate defects.
• Patent disputes over a novel ready-to-use formulation.

A conventional ANDA product is unlikely to create the same Paragraph IV exposure as a recently launched small-molecule drug with an active Orange Book patent estate. The litigation profile changes if the entrant develops a proprietary delivery system or a new stabilized liquid formulation.

How does the Solu-Medrol opportunity compare with competing corticosteroid injectables?

Product	Active ingredient	Main commercial distinction	Generic pressure
Solu-Medrol	Methylprednisolone sodium succinate	Broad hospital use, Act-O-Vial legacy	High
Depo-Medrol	Methylprednisolone acetate	Depot suspension, longer local effect	High
Solu-Cortef	Hydrocortisone sodium succinate	Emergency corticosteroid use	High
Dexamethasone injection	Dexamethasone sodium phosphate	High potency, broad acute-care use	High
Prednisolone sodium phosphate injection	Prednisolone sodium phosphate	Alternative corticosteroid injectable	Variable

Solu-Medrol competes most directly with other parenteral corticosteroids where clinicians can substitute based on potency, onset, indication, and institutional protocol. A commercial entrant should therefore compete on workflow and supply rather than assume that all demand is locked to methylprednisolone.

Key Takeaways

• Solu-Medrol is a mature methylprednisolone sodium succinate injectable with no meaningful core patent moat.
• The excipient platform centers on buffering, pH control, cake stability, rapid reconstitution, and container compatibility.
• A lactose-free 40 mg presentation is a clear formulation and labeling opportunity.
• Ready-to-use liquid products and improved dual-chamber systems offer stronger differentiation than conventional powder vials.
• The principal regulatory routes are ANDA for standard generics and 505(b)(2) for materially differentiated formulations or delivery systems.
• Device, formulation, manufacturing, and packaging patents are more commercially relevant than legacy composition-of-matter rights.
• Generic entry risk is high, but sterile supply interruptions create opportunities for reliable hospital-focused suppliers.
• Revenue exposure for Pfizer cannot be isolated from public company reporting at the individual-product level.
• The most defensible commercial strategy combines excipient differentiation with supply redundancy and hospital workflow benefits.

FAQs

Is Solu-Medrol lactose-free?

Not all presentations are lactose-free. The FDA label identifies lactose monohydrate in the 40 mg presentation and includes a warning concerning cow’s-milk protein hypersensitivity.[1]

Can methylprednisolone sodium succinate be formulated as a ready-to-use liquid?

Yes, but the development program must establish chemical stability, sterility, particulate control, container compatibility, and an acceptable shelf life. A ready-to-use product may require a 505(b)(2) regulatory strategy.

What is the best excipient replacement for lactose in Solu-Medrol?

Mannitol, sucrose, trehalose, and glycine are potential candidates. The preferred replacement depends on cake structure, reconstitution time, pH stability, residual moisture, osmolality, and injectable-product precedent.

Does Act-O-Vial provide meaningful patent protection today?

The underlying drug is not protected by a meaningful current composition-of-matter patent. Device-specific rights may be relevant to a copied dual-chamber presentation, but a conventional generic vial can avoid those design constraints.

Is a methylprednisolone sodium succinate shortage strategy commercially attractive?

Yes. Sterile injectable shortages and manufacturing interruptions create procurement opportunities for suppliers with redundant fill-finish capacity, qualified alternate excipients, reliable release testing, and hospital distribution coverage.

References

1. Pfizer Inc. (2023). Solu-Medrol (methylprednisolone sodium succinate) injection prescribing information. U.S. Food and Drug Administration labeling database.

2. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.fda.gov/Drugs

3. U.S. Food and Drug Administration. (2024). Drugs@FDA: FDA-approved drugs. https://www.accessdata.fda.gov/scripts/cder/daf/

4. Pfizer Inc. (2024). Annual report and Form 10-K. https://www.pfizer.com/investors/financial-reports-sec-filings